ClinicalTrials.gg
CompletedNCT01324323Updated Nov 25, 2019Results posted

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

A Phase 1 interventional study of Romidepsin and Rifampin in Hematologic Malignancy and Malignant Lymphoma, sponsored by Celgene. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Hematologic Neoplasms · Bristol-Myers Squibb.

Enrollment
10th of 13
14 · median 60
Started
2011
with 4 others
Phase 1
5 of 16
none open now
Registered
3rd of 16
by date

Among the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2011, is one of 5 in phase 1, and was the 3rd registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

None of the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb is open now. The open studies under Hematologic Neoplasms, anywhere →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

03

Conditions studied

  • Hematologic Malignancy
  • Malignant Lymphoma

Keywords

  • ROMI-001
  • romi
  • Romidepsin
  • Istodax
  • advanced malignancy
  • PK
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females 18 years of age or older at the time of signing the document.
  2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Must have diagnosis of advanced and must have failed other available therapies considered standard of care for their disease.
  5. (ECOG) performance status of 0 to 1.
  6. Negative urine or serum pregnancy test on females of ; and
  7. All females of childbearing potential must use an effective barrier method of (either an intrauterine contraceptive device [IUCD] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter. Female subjects should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. An in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors.

Exclusion criteria

Exclusion Criteria:

  1. Any significant medical condition or psychiatric illness that would prevent the subject from participating in the study.
  2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Subjects with significant gastrointestinal disease that may impair drug absorption, such as subjects with a history of Cohn's disease, colectomy, gastrectomy, celiac disease, or other diseases with known malabsorption.
  4. Serum potassium \< 3.8 mmol/L or serum magnesium \< 0.85 mmol/L (magnesium converts to 2.1 mg/dl or 1.7 mEq/L) (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria).
  5. Concomitant use of drugs that may cause a significant prolongation of the corrected measurement of the time between the start of the cardiac Q wave and the end of the T wave ().
  6. Concomitant use of Cytochrome P 450 3A4 () strong inhibitors within 1 week of trial medications.
  7. Concomitant use of CYP3A4 strong inducers within 2 weeks of trial medications.
  8. Concomitant use of therapeutic warfarin due to a potential drug interaction. Use of a low dose of warfarin or another anticoagulant to maintain patency of venous access port and cannulas is permitted.
  9. active infection.
  10. Known infection with (HIV), , or .
  11. Inadequate bone marrow or other organ function as evidenced by:

    • \< 9 g/dL (transfusions and/or erythropoietin are permitted);
    • (ANC) ≤ 1.0 * 10\^9 cells/L [subjects with neutropenia (ANC 1-1.5) as a function of their disease may be supported with granulocyte-colony stimulating factor (G-CSF)];
    • count \< 100 * 10\^9 cells/L or platelet count \< 75 * 10\^9 cells/L if bone marrow disease involvement is documented;
    • Total > 1.5 * (ULN) or > 2.0 * ULN in the presence of demonstrable liver ;
    • Serum /serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) > 1.5 * ULN or > 2.0 * ULN in the presence of demonstrable liver metastases; or
    • Serum creatinine > 2.0 * ULN;
  12. Prior chemotherapy treatment within 3 weeks prior to the first day of romidepsin treatment (6 weeks for nitrosoureas) or prior treatment with an agent within 4 weeks prior to the first day of romidepsin treatment.
  13. Prior radiotherapy within 4 weeks prior to the first day of treatment. Subjects who have not fully recovered or whose acute toxicity related to prior radiotherapy has not returned to baseline are ineligible.
  14. Major surgery within 2 weeks of study entry (day 1).
  15. Concomitant use of any other anti-cancer therapy.
  16. Concomitant use of any investigational agent.
  17. Prior exposure to romidepsin (other histone deacetylase [HDAC] inhibitors are allowed).
  18. Any known cardiac abnormalities, such as:

    • Congenital long measure of the time between the start of the Q wave and the end of the T wave (QT) syndrome;
    • Mean QTc formula (QTcF) interval > 450 msec;
    • A myocardial infarction within 12 months of study entry;
    • A history of coronary artery disease (CAD), e.g., angina Canadian Class II-IV. A stress imaging study should be performed for any subject whose cardiac status is uncertain. If abnormal, an angiography should be completed to define whether or not CAD is present.
    • An (ECG) recorded at screening showing evidence of cardiac ischemia (ST depression of ≥ 2 mm, measured from isoelectric line to ST segment). A stress imaging study should be performed for any subject whose cardiac status is uncertain. If abnormal, an angiography should be completed to define whether or not CAD is present.
    • Congestive Heart Failure (CHF) that meets the (NYHA) Class II to IV definitions (see Appendix F) and/or \< 40% by multi gated acquisition (MUGA) scan or \< 50% by echocardiogram and/or magnetic resonance imaging (MRI);
    • A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsades de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
    • Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);
    • Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 160/95; or
    • Any cardiac arrhythmia requiring anti-arrhythmic medication.
  19. Subjects who are pregnant or breast-feeding.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Romidepsin and rifampin

    Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8. Rifampin 600 mg oral once daily on Days 4-8

    Drug: Romidepsin · Drug: Rifampin

Interventions

  • 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

    Also known as: Istodax®, Romi, ROMI

  • 600 mg oral once daily on Days 4-8

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin

    AUC0-t: area under the plasma concentration time-curve from Time 0 to the time of the last quantifiable concentration (Ct), calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

    Time frame: Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  2. Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin

    Individual and mean romidepsin plasma concentrations by treatment and scheduled time data were collected. AUC0-24: area under the plasma concentration time-curve from Time 0 to 24 hours, calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

    Time frame: Day 1 and Day 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  3. Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).

    AUC0-∞: area under the plasma concentration time-curve from Time 0 extrapolated to infinity, calculated as \[AUCt + Ct/λz\]. λz is the apparent terminal rate constant. No AUC extrapolation was performed with unreliable λz. If the percentage of AUC extrapolated is ≥ 25%, AUC0-∞ will not be reported.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  4. Maximum Observed Plasma Concentration (Cmax)of Romidepsin

    Maximum observed plasma concentration (Cmax)was obtained directly from the observed concentration versus time data.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  5. Time to Maximum Observed Plasma Concentration (Tmax)

    Time to maximum observed plasma concentration (Tmax) was obtained directly from the observed concentration versus time data.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  6. Estimate of the Terminal Elimination Half-life in Plasma (t1/2)

    The terminal elimination half-life (t1/2) in plasma, was calculated as \[(ln 2)/λz\]. This was only calculated when a reliable estimate for λz could be obtained.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  7. Clearance (CL): Apparent Total Plasma Clearance.

    The apparent total plasma clearance (CL) was calculated as \[Dose/AUC0-∞\] for Romidepsin alone and co-administered with rifampin plasma concentrations.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

  8. Apparent Total Volume of Distribution (Vz).

    Apparent total volume of distribution (Vz) was calculated as \[(CL)/λz\] for Romidepsin and co-administered with Rifampin.

    Time frame: Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.

Secondary outcomes

  1. Summary of Participants With Treatment Emergent Adverse Events (TEAEs)

    AEs were considered related if assessed by the Investigator as possibly, probably or definitely related to study drug. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Day 1 up to Day 36 (28 days after the last treatment)

07

Results

Posted May 13, 2013

Participant flow

The study was conducted at 3 study centers (2 in the United States and 1 in the United Kingdom). The first subject was enrolled in April 2011 and the last subject completed the study in Feb 2012.

Participant flow — Overall Study
MilestoneRomidepsin and Rifampin
Started14
Completed13
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryArea Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin

AUC0-t: area under the plasma concentration time-curve from Time 0 to the time of the last quantifiable concentration (Ct), calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

Time frame:
Days 1 and 8; at 0 (pre-dose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin
ng*hr/mLRomidepsin Day 1Romidepsin and Rifampin Day 8
Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin2225.1 ± 71.43966.3 ± 76.5
Statistical analysis
  • Romidepsin Day 1 vs Romidepsin and Rifampin Day 8 · ANOVA · Ratio of the geometric mean (%): 179.3 · 90% CI 160.3 to 200.7Ratio ("Romidepsin + rifampin"/"Romidepsin") and 90% CI of the ratio of geometric means are from an ANOVA model with treatment as fixed effect and subject as random effect on the natural log transformed PK values.
PrimaryArea Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin

Individual and mean romidepsin plasma concentrations by treatment and scheduled time data were collected. AUC0-24: area under the plasma concentration time-curve from Time 0 to 24 hours, calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

Time frame:
Day 1 and Day 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin
ng*hr/mLRomidepsin Day 1Romidepsin and Rifampin Day 8
Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin2204.2 ± 72.03903.9 ± 78.0
Statistical analysis
  • Romidepsin Day 1 vs Romidepsin and Rifampin Day 8 · ANOVA · Ratio of the geometric mean: 178.3 · 90% CI 159.4 to 199.4Ratio ("Romidepsin + rifampin"/"Romidepsin") and 90% CI of the ratio of geometric means are from an ANOVA model with treatment as fixed effect and subject as random effect on the natural log transformed PK values.
PrimaryArea Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).

AUC0-∞: area under the plasma concentration time-curve from Time 0 extrapolated to infinity, calculated as \[AUCt + Ct/λz\]. λz is the apparent terminal rate constant. No AUC extrapolation was performed with unreliable λz. If the percentage of AUC extrapolated is ≥ 25%, AUC0-∞ will not be reported.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).
ng*hr/mLRomidepsin Day 1Romidepsin and Rifampin Day 8
Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).2229.8 ± 71.33980.7 ± 76.1
Statistical analysis
  • Romidepsin Day 1 vs Romidepsin and Rifampin Day 8 · ANOVA · Ratio of the geometric mean: 179.6 · 90% CI 160.5 to 201.0Ratio ("Romidepsin + rifampin"/"Romidepsin") and 90% CI of the ratio of geometric means are from an ANOVA model with treatment as fixed effect and subject as random effect on the natural log transformed PK values.
PrimaryMaximum Observed Plasma Concentration (Cmax)of Romidepsin

Maximum observed plasma concentration (Cmax)was obtained directly from the observed concentration versus time data.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)of Romidepsin
ng/mLRomidepsin Day 1Romidepsin and Rifampin Day 8
Maximum Observed Plasma Concentration (Cmax)of Romidepsin571.2 ± 81.0900.1 ± 104.9
Statistical analysis
  • Romidepsin Day 1 vs Romidepsin and Rifampin Day 8 · ANOVA · Ratio of the geometric mean: 159.1 · 90% CI 135.8 to 186.5Ratio ("Romidepsin + rifampin"/"Romidepsin") and 90% CI of the ratio of geometric means are from an ANOVA model with treatment as fixed effect and subject as random effect on the natural log transformed PK values.
PrimaryTime to Maximum Observed Plasma Concentration (Tmax)

Time to maximum observed plasma concentration (Tmax) was obtained directly from the observed concentration versus time data.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax)
hoursRomidepsin Day 1Romidepsin and Rifampin Day 8
Time to Maximum Observed Plasma Concentration (Tmax)3.0 ± 51.53.00 ± 50.7
Statistical analysis
  • Romidepsin Day 1 vs Romidepsin and Rifampin Day 8 · Wilcoxon signed-rank · p = 0.7910 · Median difference (final values): -0.15 · 90% CI -1.0 to 1.01
PrimaryEstimate of the Terminal Elimination Half-life in Plasma (t1/2)

The terminal elimination half-life (t1/2) in plasma, was calculated as \[(ln 2)/λz\]. This was only calculated when a reliable estimate for λz could be obtained.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · hours
Estimate of the Terminal Elimination Half-life in Plasma (t1/2)
hoursRomidepsin Day 1Romidepsin and Rifampin Day 8
Estimate of the Terminal Elimination Half-life in Plasma (t1/2)9.666 ± 27.98.341 ± 24.0
PrimaryClearance (CL): Apparent Total Plasma Clearance.

The apparent total plasma clearance (CL) was calculated as \[Dose/AUC0-∞\] for Romidepsin alone and co-administered with rifampin plasma concentrations.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · L/hr
Clearance (CL): Apparent Total Plasma Clearance.
L/hrRomidepsin Day 1Romidepsin and Rifampin Day 8
Clearance (CL): Apparent Total Plasma Clearance.11.59 ± 78.16.45 ± 82.2
PrimaryApparent Total Volume of Distribution (Vz).

Apparent total volume of distribution (Vz) was calculated as \[(CL)/λz\] for Romidepsin and co-administered with Rifampin.

Time frame:
Days 1 and 8; at 0 (predose), 1, 2, 3, and 4 hours (end of infusion) and at 4.25, 4.5, 5, 6, 8, 10, 12, 24 and 48 hours after the initiation of IV infusion.
Reported as:
Geometric mean · Liters
Apparent Total Volume of Distribution (Vz).
LitersRomidepsin Day 1Romidepsin and Rifampin Day 8
Apparent Total Volume of Distribution (Vz).161.48 ± 78.677.6 ± 93.8
SecondarySummary of Participants With Treatment Emergent Adverse Events (TEAEs)

AEs were considered related if assessed by the Investigator as possibly, probably or definitely related to study drug. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Day 1 up to Day 36 (28 days after the last treatment)
Reported as:
Number · participants
Summary of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsRomidepsin Plus Rifampin
= > 1 TEAE13
= > 1 TEAE related to any study drug13
= > 1 TEAE related to Romidepsin13
= > 1 TEAE related to Rifampin2
= > 1 Serious TEAE2
= > 1 Serious TEAE related to any drug1
= > 1 Serious TEAE related to Romidepsin1
= > 1 Serious TEAE related to Rifampin1
= > 1 TEAE leading to discontinuation0
= > 1 TEAE related discontinuation to any drug0
= > 1 Romidepsin related TEAE discontinuation0
= > 1 Rifampin related TEAE discontinuation0
Participants who died0

Adverse events

Collected over Day 1 up to Day 36 (28 days after last treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romidepsin Plus Rifampin—2/14 (14.3%)13/14 (92.9%)
Most frequent serious events
Most frequent serious events
EventRomidepsin Plus Rifampin
AnaemiaBlood and lymphatic system disorders2/14
VomitingGastrointestinal disorders1/14
FatigueGeneral disorders1/14
NauseaGastrointestinal disorders1/14
ThrombocytopeniaBlood and lymphatic system disorders1/14
MelaenaGastrointestinal disorders1/14
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRomidepsin Plus Rifampin
NauseaGastrointestinal disorders10/14
VomitingGastrointestinal disorders6/14
FatigueGeneral disorders6/14
Decreased AppetiteMetabolism and nutrition disorders6/14
DiarrhoeaGastrointestinal disorders5/14
ThrombocytopeniaBlood and lymphatic system disorders5/14
AnaemiaBlood and lymphatic system disorders3/14
AnxietyPsychiatric disorders3/14
ConstipationGastrointestinal disorders2/14
HypokalaemiaMetabolism and nutrition disorders2/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Romidepsin and Rifampin
Mean63.6 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)Romidepsin and Rifampin
Female9
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romidepsin and Rifampin
White13
Black or African American1
Other0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romidepsin and Rifampin
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Romidepsin and Rifampin
United Kingdom5
United States9
Height
Height(Centimeters)Romidepsin and Rifampin
Mean167.6 ± 9.54
Weight
Weight(kilograms)Romidepsin and Rifampin
Mean78.2 ± 18.85
Body Surface Area (BSA)
Body Surface Area (BSA)(Metered Squares m^2)Romidepsin and Rifampin
Mean1.9 ± 0.22

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Sarah Canon Research Institute
    Nashville, Tennessee 37203, United States
  • Sarah Cannon Research UK
    London, W1G6AD, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Feb 2012, 10 months.

Results were first posted in May 2013, 1 year 3 months after primary completion.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 10 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2011
First posted
Mar 29, 2011
StartActual
Apr 1, 2011
Primary completionActual
Feb 1, 2012
CompletionActual
Mar 1, 2012
Results first posted
May 13, 2013
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01324323
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Mar 29, 2011
Start date
Apr 1, 2011
Primary completion
Feb 1, 2012
Completion
Mar 1, 2012
Results posted
May 13, 2013
Last update
Nov 25, 2019

Study contacts

Ken Takeshita, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Romidepsin · Rifampin

Start the discussion